Nachrichten zu Amylyx Pharmaceuticals

Startseite > Aktien > Amylyx Pharmaceuticals > Nachrichten

Amylyx Pharmaceuticals Aktie

Aktie

ISIN: US03237H1014 WKN: A3DCEY SYM: AMLX Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

3,4600

USD

+2,06 %

+0,0700 USD

Letzter Kurs 02:00:00 Nasdaq

Geldkurs

10.10.24

3,4600

USD

2.700 STK

Briefkurs

10.10.24

3,4700

USD

2.300 STK

Amylyx Pharmaceuticals Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program 01.10.24 · Business Wire (engl.) · Novartis
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences 28.08.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration 12.08.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results 08.08.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 05.08.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome 02.08.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation 10.07.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide 09.07.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference 04.06.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results 09.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference 08.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 02.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals

1
2
3
4
…
5

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program 132 Leser

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ... 344 Leser
Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law ... 224 Leser
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; ... 224 Leser
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results 172 Leser
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) ... 168 Leser
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on ... 164 Leser
AMLX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with ... 164 Leser
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit ... 156 Leser
AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their ... 152 Leser
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer 152 Leser